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Abstract
Histone deacetylase inhibitors (HDACi) are increasingly used as therapeutic agents, but the mechanisms by which they alter
cell behaviour remain unclear. Here we use microarray expression analysis to show that only a small proportion of genes
(,9%) have altered transcript levels after treating HL60 cells with different HDACi (valproic acid, Trichostatin A,
suberoylanilide hydroxamic acid). Different gene populations respond to each inhibitor, with as many genes down- as up-
regulated. Surprisingly, HDACi rarely induced increased histone acetylation at gene promoters, with most genes examined
showing minimal change, irrespective of whether genes were up- or down-regulated. Many genes seem to be sheltered
from the global histone hyperacetyation induced by HDACi.
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Introduction
The post-translational modification of core histones plays a
central role in epigenetic gene regulation [1]. Modifications are
put in place by families of modifying and demodifying enzymes,
the activities of which are influenced by local concentrations of
metabolites or environmental agents [2], providing an interface by
which the environment can interact with the genome [3]. Recent
studies have begun to define the genomic distribution of specific
histone modifications and to link these to gene expression [4].
These approaches reveal associations, such as higher levels of
histone acetylation at the promoters of active genes, however, it
remains uncertain whether these modifications are a consequence
of ongoing processes (i.e. gene activity at adjacent loci), or are
predictive or causative of future transcriptional states [5].
Studies on the functional consequences of histone modifica-
tion(s) frequently use enzyme inhibitors to manipulate the
abundance of specific modifications. Salts of short chain fatty
acids (e.g. butyric, propionic, acids) occur at millimolar concen-
trations in the mammalian large intestine, and have been known
for many years to induce histone hyper-acetylation in cultured
cells [6]. They do this by inhibiting members of the histone
deacetylase (HDAC) family, enzymes which together with histone
acetyl transferases, maintain the dynamic distribution of histone
acetylation across the genome [2]. Valproic acid (VPA) is a
branched short-chain fatty acid HDAC inhibitor (HDACi) that is
used clinically as a preventive treatment for seizures and bipolar
disorder [7]. More recently VPA and other HDACi have been
shown to be effective chemotherapeutic agents [8,9], however it
remains unclear how these reagents suppress tumour cell growth.
Given the long-standing association between histone acetylation
and transcriptional activity [10], the global increases in histone
acetylation induced by HDACi might be expected to lead to
widespread increases in gene expression. However, analysis
indicates that only a small proportion of genes are up-regulated
by these agents [11,12], and whether histone acetylation changes
at these loci is controversial. Recent genome wide analysis
indicated that HDACi induce histone acetylation at transcription-
ally active, but not silenced genes [13], however a comparable
study detected only transient increases in acetylation, and
prolonged deacetylation at many genes [14]. This, and the
recognition that HDACi induce global changes in other histone
modifications [15] and impact on the acetylation of non-histone
proteins [16], suggest that the mechanisms that underpin gene
responses to HDACi are complex [17].
Here, we explore the relationship between the genome-wide
histone hyperacetylation and transcriptional responses induced by
VPA, and how this relates to histone modification at selected
genes. We find this HDACi does not increase histone acetylation
at gene promoters and coding regions, even at genes showing
enhanced transcription. This indicates that genes are often
unaffected by the HDACi-induced genome-wide histone hyper-
acetylation, and suggests that mechanism(s) other than increased
histone acetylation are responsible for the transcriptional responses
to this agent.
Materials and Methods
Cell culture and cell cycle analysis
Human HL60 (promyelocytic leukaemia) cells were cultured in
RPMI 1640 medium supplemented with 8% foetal bovine serum
(Invitrogen), 100 mg/ml streptomycin and 100 U/ml penicillin at
37uC, 5% CO2. Where required, sodium valproate (5 mM,
Sigma), SAHA (2.5 mM, gift of Dr PA Marks, Sloan-Kettering
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cycle analysis cells were washed once in Phosphate Buffered Saline
(PBS), fixed in 80% ethanol and resuspended to 10
6 cells/ml in
PBS supplemented with 1 mg/ml RNase A and 0.2 mg/ml
propidium iodide. Cells were analysed on a Coulter XL flow
cytometer.
Expression microarrays
Total RNA was isolated from HL60 cells using a Qiagen
RNeasy Mini kit, cDNA generated using Superscript III reverse
transcriptase (Invitrogen), and purified using a Qiagen PCR
purification kit according to the manufacturers’ instructions.
cDNA quality was checked by PCR amplification of a fragment
of b-actin.
cDNA was labelled with Cy3 or Cy5 using a Bioprime labelling
kit, and random primers (Invitrogen), purified using the Qiagen
PCR purification kit as above. Labelled probes were denatured
and hybridized at 42uC for 16–20 hours. Thereafter slides were
washed sequentially in 2xSSC 0.1% SDS, 0.2xSSC and
0.05xSSC. Slides were scanned using an Axon Genepix 4000B
scanner and read by Genepix 3.0 software.
Initial experiments used HGMP5K cDNA arrays with 11520
elements representing 5000 genes. Three independent experi-
ments were performed. Data was collected from the green (Cy3)
channel and quantile normalised across all samples. Student’s t-
test was used to compare results for VPA-treated and untreated
samples for each gene and calculate the significance of any
differences (p value) and false discovery rate (q value) using the R
statistical package and Q-Value software. Only genes with a q
value of less than 0.1 (i.e. a less than 10% chance of being false
positives) were taken forward for further analysis. Operon
microarrays (Operon Biotechnologies, AL, USA) contain elements
representing 25 823 genes. Labelled cDNA from VPA-treated or
untreated HL60 cells were hybridised in parallel together with
reference cDNA supplied by the manufacturers. Three indepen-
dent experiments were performed. Raw data was analysed by the
GEPAS programme [18] and Loess normalised [19]. Changes in
gene expression detected by microarray analysis were validated by
RT-qPCR using SYBR Green PCR Mastermix (Applied Biosys-
tems) and appropriate primers (Supplementary Table S1.). Expression
microarray data are MIAME compliant, and have been deposited
with the Geo database (Accession number pending).
Chromatin Immunoprecipitation (ChIP)
ChIP was performed on 5610
7 HL60 cells grown overnight in
the presence of 1 mCi/ml
3H-thymidine (Amersham). ChIP was
carried out as previously described [20]. In short, unfixed cells
were digested with micrococcal nuclease to yield mono-nucleoso-
mal fragments, incubated overnight with affinity purified rabbit
polyclonal antibodies and the antibody-bound material isolated on
protein A-sepharose beads (Invitrogen). DNA from antibody-
bound (‘Bound’) and unbound fractions (‘Unbound’) was purified
by phenol-chloroform extraction and quantified by qPCR. The
relative abundance of a modification (‘Enrichment’) from ChIP
experiments are calculated as a ratio of the material detected in the
‘Bound’ and ‘Unbound’ fractions (B/UB). As such values above 1.0
indicate that the modification is enriched at the locus detected.
Primer pairs used for analysing ChIP DNA are listed in
Supplementary Table S2. Rabbit polyclonal antisera with the
following specificities were either prepared in house; H4K8ac
Figure 1. Changes in bulk histone acetylation and cell cycle progression induced by HDACi. (A) Western blots, and (B) quantification of
the changes induced in H3K9ac, H4K8ac, H4K16ac abundance upon VPA treatment (5 mM, 8 hours). (C) Triton-acid-urea gel of histones isolated from
control (C), or VPA–treated cells over the same time course. Histone H4 associated with none, one or more acetyl residues are indicated. (D) HDACi
treatment impacts on the cell cycle. Fluorescence activated cell sorting of untreated and VPA (5 mM), SAHA (2.5 mM) or TSA (165 nM) treated cells
(8 hours). Cells associated with distinct stages of the cell cycle are indicated. Cells labelled Sub-G are either dead or apoptotic.
doi:10.1371/journal.pone.0033453.g001
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or purchased (H3K9me2, Millipore). All antibody specificities
were confirmed by inhibition ELISA and western blotting.
Results
HDACi induce genome-wide histone hyperacetylation
As a model system for these experiments, we used the human
promyeloid leukaemia cell line HL60 [21]. We have shown
previously that HL60 cells exposed to HDACi exhibit a rapid
increase in histone acetylation, which plateaus after ,8h o u r so f
treatment [15]. Western blotting with residue-specific antibodies
confirmed these data – indicating a rapid response, and similar
increases in H3 and H4 acetylation observed after eight hours of
HDACi treatment (Fig. 1A,B). Subsequent triton-acid-urea gel
analysis confirmed these changes are genome-wide (Fig. 1C), as the
bulk of histone H4 is non or mono-acetylated in untreated cells, but
,80% of histone H4 is acetylated after eight hours of treatment.
Cell cycle response to HDACi
We characterised the cellular response to three inhibitors at
concentrations that induced similar levels of global histone
hyperacetylation [22]. These include two clinically important
agents, suberoylanilide hydroxamic acid (SAHA) and sodium
valproate (VPA), and the research tool, trichostatin A (TSA). Flow
cytometric analysis of the DNA content of treated cells indicate
that HDACi induce changes in cell cycle progression, but the
profiles show subtle differences. All three agents induce an
accumulation of cells in G2/M, but this is more pronounced with
SAHA and TSA, which also stimulate apoptosis. In contrast, VPA
leads to an accumulation of material in G2/M but minimal
apoptosis (Fig. 1D).
Gene expression changes in HDACi-treated cells
As an initial screen to identify genes in HL60 cells whose
expression changes in response to HDACi, we exposed log-phase
cells to the same inhibitor treatment regimens. Cells were treated
for eight hours and cDNA from treated and untreated cells
hybridized to HGMP5k cDNA arrays. The labelling intensities of
probes hybridized with cDNA from treated and untreated samples
were compared (t-test) and the significance of the difference (p-
value) calculated (See Methods for details of data processing). Analysis of
the responding genes showed a number of unexpected findings
(Fig. 2A). Of ,5000 genes on the slide, only 369 (,7%) showed a
Figure 2. Changes in transcript level induced by HDACi. (A) Venn diagram showing genes where transcript levels changed significantly
(p,0.01) in response to HDACi, detected by HGMP 5K array (5000 gene probes). HL60 cells were treated with VPA (5 mM), SAHA (2.5 mM) or TSA
(165 nM) for eight hours. (B) RT-qPCR was used to quantify the transcriptional change at genes that responded to all three HDACi. HL60 cells were
treated with VPA (5 mM, 8 hours). Transcript abundance was normalised to b-actin, and presented on a base 2 logarithmic scale. Values are
presented with a standard error of mean (n=3). (C) Cells were treated with VPA (5 mM), and transcript abundance analysed at defined time points
using Operon microarrays (25823 genes). Quantitative presentation of the number of genes that were more than 2-fold up-regulated (Shaded bars)o r
down-regulated (Filled bars) at time points during the time course. (D) RT-qPCR was used to quantify the transcriptional change at genes that
responded to VPA (5m M ) at 1, 2 and 8 hours treatment. Genes show divergent responses, including early and continued up-regulation (ANXA2, DLK1,
IL1B, KIF3C), little initial change and subsequent down-regulation (MCM7, PES1, LMO2) or early and persistent down-regulation (MYC). Transcript
abundance was normalised to b-actin, and presented on a base 2 logarithmic scale.
doi:10.1371/journal.pone.0033453.g002
Transcriptional and Epigenetic Responses to HDACi
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33453significant (p,0.01) change in response to VPA, of which broadly
equivalent numbers of genes were down-regulated (154 genes) as
up-regulated (215 genes). Similar responses were also induced by
the hydroxamic acid-based HDACi, TSA and SAHA. Both agents
induced transcriptional change at a small proportion of genes
(SAHA, 258 genes (5%); TSA: 675 genes (13%)), with broadly
equivalent numbers being down- and up-regulated. Although all
three agents induced similar patterns of response, this involved
distinct populations of genes (Fig. 2A), even with TSA and SAHA
which share a common structural identity. Importantly, only seven
of 1167 responding genes respond to all three agents, despite all
inhibitors inducing similar degrees of histone hyperacetylation.
These results were validated by re-analysing selected genes that
showed a maximal response to VPA treatment (within the top
10%). Real time PCR analysis (Fig. 2B) confirmed both the
direction, and magnitude of the transcriptional response at these
loci.
Identifying genes showing early VPA-induced changes in
transcription
Our subsequent studies focussed on identifying VPA-responding
genes at early time points, as we reasoned that these are more
likely to be induced by the direct action of the inhibitor. To do
this, we used a larger array (25 823 genes), allowing us to identify
the few genes that showed changes in transcript abundance (.2-
fold) after only one hour of treatment (223 genes, 0.8%). The
maximal transcriptional response was at two hours (2134 genes,
Fig. 2C). These data are consistent with the earlier study, in that
only a small proportion of genes respond to VPA (,9%, 2 hours),
and that as many genes are down-regulated as up-regulated, even
Figure 3. Histone modification distribution on genes up-regulated by VPA. Chromatin immunoprecipitation analysis of histone
modifications on two VPA-responsive genes: KIF3C and RERE. Graphs indicate the enrichment of histone modifications at specific primer pairs in
untreated cells (Control), and after eight hours of VPA treatment (+VPA). Histone modification enrichment is shown as a bound:unbound ratio. The
primers used are indicated on gene diagrams, which also indicate the transcription start site (TSS), exons (Empty boxes), and untranslated regions
(Filled boxes). The abundance of a histone modification (‘Enrichment’) is calculated from the ratio of material detected in bound:unbound fractions.
doi:10.1371/journal.pone.0033453.g003
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regulated).
These data were validated by RT-qPCR, focussing on genes
that showed early increases in expression, or were down-regulated
after protracted VPA treatment. Transcriptional activity was
probed at several time points through the VPA treatment to assess
the complexity of transcriptional responses (Fig. 2D). Interestingly
the majority of genes showed progressive changes in expression –
with both up-regulated (ANXA2, DLK1, ILB, KIF3C), and down-
regulated genes (PES1, MYC) showing consistent behaviour
throughout the timecourse. For two genes (MCM7, LMO2), an
initial (small) up-regulation (1 h) was followed by much more
pronounced down-regulation (8 hr).
Gene-specific changes in histone modification
The expression analyses described indicate that VPA stimulates
transcriptional responses at a subset of genes. We used chromatin
immunoprecipitation to assess whether transcriptional activation
correlated with increased histone acetylation at two VPA up-
regulated genes - KIF3C (7-fold increase) and RERE (2-fold increase)
(Fig. 3). Epigenome mapping indicates that the TSS of active genes
show enhanced levels of acetylated histones [13], so we focussed
on these regions. Acetyl marks are not functionally interchange-
able, so we analysed a highly abundant acetyl mark (H4K16ac),
along with marks found in moderately acetylated (H4K8ac) or
hyperacetylated chromatin (H3K9ac) [23–25].
This analysis showed acetylation distributions on these genes in
untreated cells are as expected. H3K9ac, a mark associated with
hyperacetylated chromatin, showed significant enrichment at the
TSS (Primer 3, KIF3C; Primer 1, RERE), but not at sites either
upstream or within the body of the genes. In contrast, the more
abundant acetyl marks, H4K8ac and H4K16ac, were not
enriched within these genes. These data are consistent with
previous studies [13]. However the distribution of acetyl marks
after VPA treatment was surprising. We predicted that levels of
acetylation would increase, given the increased gene activity at
these two genes. However, our data did not show this – detecting
either pronounced (H3K9ac, H4K8ac), or modest (H4K16ac) falls
at the sites analysed. These changes were most significant at
promoter-proximal regions, where acetylation levels were rela-
tively high in untreated cells. In contrast, other histone marks act
as expected. H3K4me3, a mark associated with transcriptional
activation, is highly enriched on both gene promoters in untreated
cells, and shows a modest increase upon VPA treatment (Fig. 3).
Similarly, both genes are associated with low levels of the
‘repressive’ mark H3K9me2, which did not significantly change
upon VPA treatment (Fig. 3).
Levels of H3K8ac and H4K16ac were also assessed on the
VPA-responsive genes, CD53,( 11-fold increase) and BRAF (2-fold
increase) and also showed minimal changes in histone acetylation
upon VPA treatment (Data not shown). Thus, for all four genes,
there is a mismatch between the genome-wide hyperacetylation
Figure 4. Histone acetylation changes on up-regulated genes during extended VPA treatment. Chromatin-immunoprecipitation analysis
of H4K8ac and H3K9ac on up-regulated genes (BRAF, CD53, RERE, KIF3C) in response to VPA treatment (5 mM). Analysis was performed on either
untreated cells (Control), or during VPA treatment (15, 60 & 240 minutes). Primer locations are indicated on the gene diagrams. The abundance
of a histone modification (‘Enrichment’) is calculated from the ratio of material detected in bound:unbound fractions.
doi:10.1371/journal.pone.0033453.g004
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acetylation at promoter regions.
Time course of histone modification changes on
transcriptionally up-regulated genes
The absence of significant increases in histone acetylation at
VPA-induced genes was unexpected, but could reflect a gene’s
varied transcriptional response over the 8-hour treatment, which is
not captured at a single timepoint. We therefore analysed histone
acetylation at multiple points during the treatment, focussing on
genes which are up-regulated over this timecourse (BRAF, CD53,
RERE, KIF3C; Fig. 2B). We analysed acetyl marks (H3K9ac,
H4K8ac) which have been extensively characterised, and shown to
be associated with transcriptionally active promoters [13],
However, as before, the abundances of these acetylated isoforms
either remain unchanged, or show gradual and progressive
decreases at all gene promoters (Fig. 4). Both marks tend to show
similar behaviour at the same locus, but the decreases in H3K9ac
are generally more marked (i.e. on the RERE promoter), reflecting
its higher abundance in untreated cells.
Finally, we extended this experiment to analyse three classes of
genes – (i) a gene those that showed early and progressive up-
regulation (DLK1, Fig. 5A), (ii) genes that show down-regulation
(LMO2, MYC, Fig. 5B), and (iii) an abundant repetitive element,
ALU (Yb8) (Fig. 5C). In all cases H4K8ac abundance was low at
promoter-proximal loci (i.e. B/UB rations lower than 1.0),
however small progressive increases (i.e. DLK1) or decreases (i.e.
LMO2, MYC) in the modification were detected though the time
course. Interestingly, ALU repeat sequences, which account for
,25% of the human genome, show a progressive increase in
H4K8ac in VPA-treated cells, indicating that at least some repeat
elements are susceptible to hyperacetylation in response to
HDACi.
Discussion
It has long been thought that the functional effects of HDACi
are mediated by their ability to induce global histone hyperace-
tylation, which was presumed to induce transcriptional responses
at key genes. However, recent studies indicate that large numbers
of proteins are acetylated in response to HDACi, including key
transcription factors and metabolic enzymes [16], suggesting that
other mechanisms may contribute to HDACi activity. The data
we present here suggest that these agents induce substantial
changes in gene expression, but only at a subset of genes.
Figure 5. Histone acetylation changes on up- and down-regulated genes during extended VPA treatment. Chromatin-
immunoprecipitation analysis of H4K8ac on: (A), Up-regulated gene (DLK1), (B), Down-regulated genes (LMO2, MYC)o r( C), repetitive elements
(ALU) in response to VPA treatment (5 mM). Analysis was performed on either untreated cells (Control), or during VPA treatment (15, 60 &
240 minutes). Primer locations are indicated on the gene diagrams. The abundance of a histone modification (‘Enrichment’) is calculated from the
ratio of material detected in bound:unbound fractions.
doi:10.1371/journal.pone.0033453.g005
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response is not straightforward.
Our results show that many genes are sheltered from the global
histone hyperacetylation induced by HDACi. This is consistent
with our finding that only a small proportion of genes show
significant transcriptional changes in response to HDACi (,9%),
and that as many are down-regulated as activated, even after short
periods of inhibitor treatment when transcriptional effects are
likely to be direct (Fig. 2C). Furthermore, the finding that different
inhibitors induce responses at distinct subsets of genes suggests that
their functional effects are put in place via different pathways,
rather than via their shared ability to induce histone hyperacetyla-
tion (Fig. 2A).
Subsequent analysis of histone modification distributions on
VPA-responsive genes showed that, irrespective of transcriptional
response, histone acetylation at gene promoters does not reflect the
inhibitor–induced increase in bulk histone hyperacetylation. Even
after longer inhibitor treatments, of the eight genes examined only
one, DLK1, showed a modest increase in H4 acetylation. This is a
small sample, but includes all the genes that show the largest
transcriptional responses to HDACi treatment (Fig. 2B), suggesting
that our findings are representative of most genes. It seems that
local levels of histone acetylation are determined by gene specific
factors rather than induced changes in global histone modification.
While there are examples of individual promoters that fail to show
enhanced acetylation in response to HDACi (e.g. MMTV, [26]),
they have been seen as counterintuitive exceptions, and most
reports focus on increased histone acetylation in response to
HDACi (e.g., [13]). This remains controversial, as a recent study
found HDACi induced transient increases in promoter acetylation
at a subset of genes, but deacetylation after prolonged exposure (2–
6 hrs) was a more typical response [14]. Our data is consistent
with this, and suggests that many promoters show minimal change
in response to HDACi and that genes showing increased
acetylation, such as the Hoxb genes [27] are the exception rather
than the rule.
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